Background illustration for clinical trials search

Paid Clinical Trials Princeton

Discover 1,664 paid clinical trials in Princeton, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,664

FeaturedActive & Responsive

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

for

Rheumatoid Arthritis

Location: West Long Branch NJ, Great Neck NY, Duncansville PA,

Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06972446

Phase2, Recruiting

Featured

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

for

Non Small Cell Lung Carcinoma

Location: East Brunswick NJ, Easton PA, Shirley NY, Leesburg VA,

Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06772623

Phase1, Phase2, Recruiting

Featured

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for

Non-Small Cell Lung Cancer

Location: East Brunswick NJ, Teaneck NJ, The Bronx NY,

Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06568939

Phase2, Recruiting

Featured

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for

Non-Small Cell Lung Cancer

Location: East Brunswick NJ, Lebanon NH, Brampton, Fort Wayne IN,

Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07155187

Phase2, Phase3, Recruiting

Featured

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

for

Breast Cancer

Location: East Brunswick NJ, Jacksonville FL, Kansas City MO,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07368998

Phase2, Recruiting

Featured

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

for

Colorectal Cancer

Location: East Brunswick NJ, Lake Success NY, New Haven CT,

Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07525206

Phase3, Recruiting

Featured

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

for

HER2-positive Breast Cancer

Location: East Brunswick NJ, Shirley NY, Albany NY, Toronto,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07413939

Phase2, Phase3, Recruiting

Featured

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for

Breast Cancer

Location: East Brunswick NJ, Florham Park NJ, New York NY,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06790693

Phase3, Recruiting

Featured

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for

Moderately to Severely Active Crohns Disease

Location: New Brunswick NJ, Moorestown NJ, Philadelphia PA,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06819891

Phase3, Recruiting

Featured

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

for

Lymphoma

Location: New Brunswick NJ, Stony Brook NY, New Haven CT,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06084936

Phase3, Recruiting

Featured

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for

Epithelial Ovarian Cancer, Fallopian Tube Cancer,

Location: New Brunswick NJ, Philadelphia PA, Bethlehem PA,

Sponsor: AbbVie

Sex: Female

Age: 18+

Code: NCT06890338

Phase2, Recruiting

Featured

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for

Breast Cancer

Location: New Brunswick NJ, Philadelphia PA, The Bronx NY,

Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07100106

Phase1, Phase2, Recruiting

Featured

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

for

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis,

Location: Warren Township NJ, Freehold NJ, New York NY, Carmel NY,

Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06318169

Phase3, Recruiting

Featured

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

for

Alzheimers Disease

Location: Ridgewood NJ, Springfield NJ, Plymouth Meeting PA,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 50 - 70+

Code: NCT07177352

Phase3, Recruiting

Featured

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

for

Ulcerative Colitis

Location: Morristown NJ, Philadelphia PA, Pittsburgh PA,

Sponsor: AbbVie

Sex: All

Age: 2 - 17

Code: NCT07071519

Phase3, Recruiting

Featured

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

for

Crohn's Disease

Location: Morristown NJ, New York NY, Waltham MA, Cleveland OH,

Sponsor: AbbVie

Sex: All

Age: 2 - 17

Code: NCT05995353

Phase3, Recruiting

Featured

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

for

Migraine

Location: Morristown NJ, Philadelphia PA, Stamford CT,

Sponsor: AbbVie

Sex: All

Age: 6 - 17

Code: NCT05125302

Phase3, Recruiting

Featured

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

for

Episodic Migraine

Location: Morristown NJ, Philadelphia PA, Amherst NY, Franklin VA,

Sponsor: AbbVie

Sex: All

Age: 6 - 17

Code: NCT05711394

Phase3, Recruiting

Featured

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

for

Neovascular Age-related Macular Degeneration

Location: Little Silver NJ, Philadelphia PA, Towson MD,

Sponsor: AbbVie

Sex: All

Age: 50+

Code: NCT07007065

Phase3, Recruiting

Featured

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

for

Depression, Bipolar I Disorder

Location: Irvington NJ, Cleveland OH, West Chester OH,

Sponsor: AbbVie

Sex: All

Age: 10 - 17

Code: NCT04777357

Phase3, Recruiting

Paid Clinical Trials Princeton

Filter results

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Interested in new trials?

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.